NCBiotech News

Morrisville-based Heat Biologics has signed a definitive merger agreement to acquire Elusys Therapeutics, a biodefense company that makes a treatment for anthrax, a deadly infectious disease potentially spread by bioterrorism or biowarfare.

A new national public/private consortium designed to boost the development of gene therapies also holds promise for North Carolina, as a major global leader in cell and gene therapies.

Morrisville-based Metabolon, a metabolomics data and insights company, will work with two major medical centers in Boston to study the biology underlying lactation for better maternal and infant health.

Marken, a global logistics company that serves the pharmaceutical and life sciences sectors, has expanded its headquarters and regional distribution operations in Durham to meet growing demand for shipment of clinical drug supplies, especially cell and gene therapies.

NCBiotech and a statewide coalition of partners are a Phase 1 recipient of up to $500,000 in the U.S. EDA’s $1 billion Build Back Better Regional Challenge.

Five years after launching with a team headlined by local life sciences “rainmaker” Steve Butts and $49 million in capital, Morrisville-based Arrivo BioVentures is emerging from stealth mode with four drugs in its pipeline.

Medicago, a Canadian biopharmaceutical company with manufacturing operations in Durham, is reporting positive results from a Phase 3 clinical trial of its potential COVID-19 vaccine made in plants.

Quebec-based Mispro Biotech Services says it will open a new RTP vivarium in early 2022 to support North Carolina’s globally recognized life sciences research community.

Thermo Fisher Scientific says is planning to build a 375,000-square-foot manufacturing plant in Mebane that will create 150 to 200 jobs, with help from a $192.5 million federal contract.

GreenLight Biosciences, which has a growing research and development presence in Research Triangle Park, has announced additional financing on its journey to becoming a publicly traded company

Durham-based BioCryst Pharmaceuticals has reached agreements that will provide the company with $350 million in funding to support the development of two of its new drugs.

Regulatory authorities in Mexico have approved RTP ag tech company Vestaron’s SPEAR-Lep, a biopesticide that’s already in use in the U.S.

Durham-based Cell Microsystems has received $10 million in financing from life science and venture capital firm Telegraph Hill Partners.

Sheila Mikhail, co-founder and CEO of AskBio and an NCBiotech board member, has been named national Entrepreneur of the Year by Ernst & Young.

Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.